Rigel Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The ESG score includes 17 United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Life below Water'. This dashboard includes a Q&A table about Rigel Pharmaceuticals Inc. Jump to the end of this page for potential risks for Rigel Pharmaceuticals Inc based on sector, location and size.
Rigel Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 4.0, social score of 6.4 and governance score of 6.4.
5.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 579 | Tonix Pharmaceuticals Holding Corp | 5.7 | High |
| 579 | VIVA Biotech Holdings | 5.7 | High |
| 602 | Rigel Pharmaceuticals Inc | 5.6 | High |
| 602 | Celltrion Inc | 5.6 | High |
| 602 | Adaptimmune Therapeutics PLC | 5.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Rigel Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Rigel Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Rigel Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Rigel Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Rigel Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Rigel Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Rigel Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.